Search
Relay Therapeutics Inc
RLAYAdd to Watchlist
17.300USD
+0.240+1.41%
Close 10-15 16:00（ET）
3.73BMarket Cap
LossP/E TTM
Relay Therapeutics Inc (RLAY) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Relay Therapeutics Inc in the past month.
Buy
5 Strong Buy
8 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
27.273USD+57.10%
RLAY Analyst Recommendation Trends
In the current month, RLAY has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RLAY average Analyst price target in the last month is 27.273.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
5
5
5
5
6
6
6
6
8
8
9
7
7
6
6
6
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
13
14
12
13
13
12
12
RLAY Analyst Rating for Peer Comparison
Updated: Oct 15, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Revolution Medicines Inc
RVMD
9
14
1
0
0
24
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
7
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Financial Forecasting
Based on analysts' estimates, RLAY EPS is projected to reach -0.397 in FY2026Q3, following reported EPS of -0.413 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.40
-0.38
-0.39
-0.40
-0.37
Actual
-0.32
-0.41
-0.41
--
--
Surprise
+21.73%
-8.14%
-5.52%
--
--
FAQs
What is Relay Therapeutics Inc's expected revenue for the next quarter?
Relay Therapeutics Inc's expected revenue is 235.00K.
What is Relay Therapeutics Inc's price target?
Analysts forecast that Relay Therapeutics Inc's price target is USD 27.27, with the highest forecast at USD 32.00 and the lowest forecast at USD 20.00.
How have Relay Therapeutics IncRLAY's recent earnings per share performed?
The market expectation was USD -0.41, while Relay Therapeutics IncRLAY's earnings per share (EPS) for the previous quarter was USD -0.41. EPS for the next quarter is expected at USD -0.40.
What is the analyst rating for Relay Therapeutics Inc?
Based on the ratings of Relay Therapeutics Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.